Loading...
Loading...
BBLGW| Name | Value |
|---|---|
| Revenues | 0.0K |
| Cost of Revenue | 0.0K |
| Gross Profit | 0.0K |
| Operating Expense | 1,160.0K |
| Operating I/L | -1,160.0K |
| Other Income/Expense | -389.9K |
| Interest Income | 0.3K |
| Pretax | -1,549.9K |
| Income Tax Expense | -0.3K |
| Net Income/Loss | -1,549.9K |
Bone Biologics Corporation is a medical device company specializing in bone regeneration for spinal fusion using the recombinant human protein NELL-1/DBX. Their combination product offers targeted control over bone regeneration, particularly for spinal fusion procedures in skeletally mature patients with degenerative disc disease at one level from L4-S1. The company's platform technology has broad applications in surgical specialties such as spinal, orthopedic, plastic reconstruction, neurosurgery, interventional radiology, and sports medicine. Bone Biologics holds a license agreement with the UCLA Technology Development Group to develop and commercialize NELL-1 for spinal fusion applications.
